Australian authorities (TGA) first to grant final product approval for Intercell's Vaccine to Prevent Japanese Encephalitis

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

new product

Wien (euro adhoc) - Vienna, Austria, January 23, 2009 - Intercell AG
(VSE: ICLL) today announced that the Australian Therapeutic Goods
Administration (TGA) granted product approval for the company's
vaccine to prevent Japanese Encephalitis. This final decision step
for the new vaccine follows the positive recommendation provided by
Australian Drug Evaluation Committee (ADEC) in December 2008.

This decision of the Australian authorities represents the first
regulatory approval for the vaccine in any country. Intercell has
been successfully advancing parallel regulatory processes in all key
markets for travelers and military personnel with an imminent product
approval in the U.S. Following the CHMP positive opinion of the
European Medicines Agency (EMEA) obtained in December 2008, the
approval by the European Union providing formal market authorization
for all 27 member states as well as for Norway and Iceland will
follow within the next weeks according to the defined EMEA process.

"We are very pleased that all approval processes for our novel
Japanese Encephalitis vaccine have proceeded in line with our planned
timelines. We are now moving forward to bring this important product
to both travelers and military personnel in early 2009", states
Thomas Lingelbach, Chief Operating Officer of Intercell.

Japanese Encephalitis is a deadly disease that kills as many as 30%
of those who manifest the disease. Japanese Encephalitis is only
becoming a larger risk for travelers. There is increasing travel to
rural areas where the disease is more common, and climate change is
extending the range of disease-carrying mosquitoes.

Intercell's vaccine will be the only registered JE-vaccine available
in the Australian market and will be distributed and marketed by CSL
Biotherapies Pty Ltd., which has the exclusive right for marketing
and distribution of the novel cell culture-based vaccine in
Australia, New Zealand, Papua New Guinea and Pacific Islands (trade
name JESPECT®). Intercell is committed to make JESPECT® available to
the Australian market as soon as possible.

Intercell's vaccine is a purified, inactivated product for active
immunization against viral infections of Japanese Encephalitis. The
vaccine is manufactured in Intercell's proprietary manufacturing
facility in Scotland and is prepared using tissue culture rather than
live organisms.

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes
30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths.
Up to 50% of survivors have persistent neurological sequelae.
Japanese Encephalitis is the leading cause of viral neurological
disease and disability in Asia and the most important viral
encephalitis in Asia. The disease is most common in several
developing countries in Asia. No treatment is currently available;
only vaccination effectively prevents the disease. Though other
vaccines have been available in the past, use of those products was
limited due to reports of neurological reactions.

About Intercell's JE vaccine

Intercell's novel JE vaccine is a purified, inactivated vaccine for
active immunization against the Japanese Encephalitis virus. The
vaccine was developed for over 10 years under a Collaborative
Research and Development Agreement (CRADA) with the Walter Reed Army
Institute of Research (WRAIR). Intercell's Phase III trials for the
vaccine found that the vaccine demonstrated excellent immunogenicity
against Japanese Encephalitis and an overall clinical safety profile
similar to placebo combined with an excellent local tolerability
profile. These data were published in The Lancet in December 2007:

» The immunogenicity was comparable to that of the U.S. licensed
product, JE-VAX® » Intercell's vaccine demonstrated an overall
clinical safety profile similar to placebo » Further, Intercell's
JE vaccine had an excellent local tolerability profile in the
head-to-head study with JE-VAX®

In December 2008 Intercell AG received the CHMP (European Committee
for Human Medicinal Products) positive opinion for the approval of
its vaccine in Europe. Furthermore, the Australian Drug Evaluation
Committee (ADEC) has issued a positive approval recommendation for
the company´s new vaccine against Japanese Encephalitis.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market